Lexicon Pharmaceuticals presented its Phase IIb data for pilavapadin (LX9211) on 3 March as a win that clarified the dosing regimen to take into Phase III in diabetic peripheral neuropathic pain (DPNP), but shareholders apparently had a different takeaway from the 496-patient PROGESS study, which Lexicon admitted had missed its primary endpoint.
Lexicon’s Sunny Take Does Not Sway Investors About Phase IIb DPNP Miss
While Lexicon’s non-opioid pain candidate missed the primary endpoint in a diabetic peripheral neuropathic pain study, the company insisted the data revealed a path forward with a 10mg daily dose.
More from Clinical Trials
• By
RemeGen is planning to complete enrolment in the global Phase III RemeMG study with telitacicept in generalized myasthenia gravis by the end of 2025 or early 2026. The Chinese firm has already sidelined two other global Phase III trials with the molecule to prioritize the indication.
• By
The biotech is banking on itolizumab’s longer-term efficacy as well as unmet need in frontline acute graft-versus-host disease as it prepares to meet with the FDA.
• By
The head of the Spanish medical dermatology specialist told Scrip that maintaining the status quo will only result in the continent’s life sciences sector slipping further behind the US and China.
• By
With its exon 53-skipping candidate already showing promise in 24-week data, Wave now has 48-week data showing improvements in muscle health and functional outcomes.
More from Therapy Areas
• By
After a long wait for patients, Vykat has become the first drug approved for Prader-Willi syndrome symptoms, opening the market up for Soleno and future challengers.
• By
With its exon 53-skipping candidate already showing promise in 24-week data, Wave now has 48-week data showing improvements in muscle health and functional outcomes.
• By
J&J is confident that its bispecific antibody/kinase inhibitor combo’s overall survival win over AstraZeneca’s single-agent pill will shift the standard of care.